Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07093554 | Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 | 31 | Medical College of WisconsinOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT07313943 | PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGE(HL PAX5- 2025) | recruiting | — | 60 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER |
| 2 |
| Jan 2, 2026 |
| clinicaltrials |
| NCT07313982 | LEF1 EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A MARKER FOR DIAGNOSIS AND SURVIVAL PREDICTION(LLC/LEF1 2024) | recruiting | — | 350 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04991103 | Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) | recruiting | Phase 2 | 40 | University of Alabama at BirminghamOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05260957 | CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). | recruiting | Phase 2 | 22 | Lazaros LekakisOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07093710 | Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 101 | Sun Yat-sen UniversityOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07312188 | A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 2 | 90 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07312630 | Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies | recruiting | Early Phase 1 | 19 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT00177268 | Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research | recruiting | — | 200 | University of PittsburghOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05157581 | Extracorporeal Photopheresis in Sezary Syndrome(ECP) | recruiting | — | 20 | Oleg E. Akilov, MD, PhDOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05816850 | Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial(FIL_FOLL-BIO) | recruiting | — | 654 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06008691 | A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice(FIL_MAB) | recruiting | — | 1,500 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06522932 | PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy | recruiting | Phase 1 | 32 | Michael RandallOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06588205 | Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma(FIL_MIMYC) | recruiting | — | 200 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT07100067 | LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | N/A | 35 | Nanjing Legend Biotech Co.INDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT00398177 | Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease | recruiting | — | 9,999 | Stanford UniversityOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05642884 | Prehabilitation Feasibility Among Older Adults Undergoing Transplantation | recruiting | N/A | 30 | Noha Mohamed SharafeldinOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT05695508 | GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5(HD10/DSMMXX) | recruiting | Phase 2 | 160 | University of Heidelberg Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT06392477 | A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 96 | SanofiINDUSTRY | 5 | Dec 23, 2025 | clinicaltrials |
| NCT07253129 | Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)(T-START-PR) | recruiting | — | 88 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06247189 | ICOPE Program Feasibility in the Management of Myeloma Patients(Onco-ICOPE) | recruiting | N/A | 30 | University Hospital, ToulouseOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07296627 | Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients(PRIMARY) | recruiting | — | 500 | Peking University People's HospitalOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07283796 | A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma | recruiting | Phase 1 | 110 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07294625 | A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05192122 | Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD(HEME-20) | recruiting | Phase 1 | 50 | University of Illinois at ChicagoOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06736613 | A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma | recruiting | Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07062627 | Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma | recruiting | Phase 2 | 12 | Hyungwoo ChoOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07189065 | A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 150 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07283822 | Amping up With PemJAK | recruiting | Phase 2 | 53 | Seda S. ToluOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07284927 | Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies | recruiting | Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07285590 | Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma(IMCL-2023) | recruiting | Phase 2 | 50 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 2 | Dec 16, 2025 | clinicaltrials |
| NCT04268199 | A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment(EASE) | recruiting | Phase 2 | 100 | AHS Cancer Control AlbertaOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07052695 | Mosunetuzumab for CLL MRD Clearance | recruiting | Phase 1 / Phase 2 | 40 | Inhye AhnOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06518551 | Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM | recruiting | Phase 1 / Phase 2 | 49 | Omar Nadeem, MDOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07179679 | A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors | recruiting | Phase 1 | 42 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05602363 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | recruiting | Phase 1 | 120 | Carna Biosciences, Inc.INDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT06251076 | Plan Development for Giving Teclistamab in the Outpatient Setting | recruiting | Phase 4 | 15 | University Health Network, TorontoOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT02863692 | Registry of the German CLL Study Group(CLL-Registry) | recruiting | — | 8,000 | German CLL Study GroupOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05556928 | Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry(CARE-Heme) | recruiting | — | 5,000 | University of Alabama at BirminghamOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06156774 | SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project | recruiting | — | 130 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06803693 | Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | recruiting | Phase 2 | 152 | Ruijin HospitalOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT04925609 | Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors(Briga-PED) | recruiting | Phase 1 / Phase 2 | 65 | Princess Maxima Center for Pediatric OncologyOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05168930 | Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | recruiting | Phase 2 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06421948 | Linperlisib Combined With Chidamide in Patients With PTCL | recruiting | Phase 1 / Phase 2 | 134 | Yanyan LiuOTHER_GOV | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06986174 | A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia | recruiting | Phase 2 | 30 | Shayna Sarosiek, MDOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06390956 | Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) | recruiting | Phase 2 | 23 | University of UtahOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06520163 | Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma | recruiting | Phase 3 | 99 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06237803 | European Myeloma Network (EMN) Sample Project(EMN36) | recruiting | — | 6,000 | European Myeloma Network B.V.NETWORK | 10 | Dec 3, 2025 | clinicaltrials |
| NCT06485076 | Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma(EPC-MM+L) | recruiting | N/A | 144 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 5, 2026source: clinicaltrials